Key clinical point: Ramucirumab in combination with irinotecan fails to improve the progression-free survival (PFS) rate at 6 months in patients with previously treated advanced gastric cancer.
Major finding: The 6-month PFS rate was 26.5% ( P = .1353). The median PFS was 4.2 months, and the median overall survival was 9.6 months. The most common grade ≥3 adverse events were neutropenia (51%), leucopenia (43%), anemia (20%), anorexia (14%), and febrile neutropenia (11%). There were no treatment-related deaths or new safety signals.
Study details: This study was a single-arm, phase 2 multicenter trial of 35 patients ( HGCSG 1603 ) with previously treated advanced gastric cancer who received the second-line ramucirumab plus irinotecan. The primary endpoint was the 6-month PFS rate.
Disclosures: This study was supported by Eli Lilly Japan K.K. Several of the authors received honoraria or research funding or declared ownership interests outside this work, including with Eli Lilly Japan.
Source: Kawamoto Y et al. Phase II study of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with advanced gastric cancer: HGCSG1603. Oncologist. 2022 (May 17). Doi: 10.1093/oncolo/oyac086